Cerebral palsy (CP) is a common pediatric neuromotor disorder that is characterized by persistent impairments in movement, muscle tone, and posture. It is frequently associated with sensory, cognitive, and behavioral comorbidities. This guideline presents evidence-based recommendations for neurorestorative therapy in pediatric CP, developed through a systematic review of 44 studies (including randomized controlled trials, cohort studies, and systematic reviews) published up to December 31, 2024. Recommendations were graded according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. Key recommendations include the use of the Gross Motor Function Classification System for precise motor dysfunction grading, neuroimaging-supported diagnostic criteria, and a multidisciplinary neurorestorative treatment approach. This approach encompasses cell therapy (Grade B), pharmacological management (Grades B–C), surgical interventions (Grade B), neuromodulation (Grade B), structured rehabilitation (Grade B), and psychological support (Grade C). The guideline also advocates for a multi-tiered prevention strategy targeting primary, secondary, and tertiary levels. By emphasizing evidence-based, individualized, and multidisciplinary care, this guideline aims to optimize neurorestorative outcomes and improve quality of life for children with CP, while encouraging ongoing research and periodic updates as new evidence emerges.